Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-Escalation Study of R1507 [RO4858696] in Patients With Advanced Solid Tumours.

Trial Profile

A Dose-Escalation Study of R1507 [RO4858696] in Patients With Advanced Solid Tumours.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teprotumumab (Primary)
  • Indications Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 26 Mar 2021 Results of a population PK analysis using data from three clinical studies: NCT00400361, NCT01868997 and NCT03461211 published in the Clinical Pharmacokinetics
    • 23 Sep 2020 Results assessing pharmacokinetics and exposure-response relationship of Teprotumumab in this and Phase 2 and 3 studies presented at the 2020 American College of Clinical Pharmacology Annual Meeting
    • 14 May 2020 Results published in the Horizon Therapeutics plc Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top